| Literature DB >> 32589921 |
Sarah A Holstein1, Alan Howard2, David Avigan3, Manisha Bhutani4, Adam D Cohen5, Luciano J Costa6, Madhav V Dhodapkar7, Francesca Gay8, Nicole Gormley9, Damian J Green10, Jens Hillengass11, Neha Korde12, Zihai Li13, Sham Mailankody12, Paola Neri14, Samir Parekh15, Marcelo C Pasquini16, Noemi Puig17, G David Roodman18, Mehmet Kemal Samur19, Nina Shah20, Urvi A Shah12, Qian Shi21, Andrew Spencer22, Vera J Suman21, Saad Z Usmani4, Philip L McCarthy11.
Abstract
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup has organized an annual workshop focused on minimal residual disease (MRD) testing and immune profiling (IP) in multiple myeloma since 2016. In 2019, the workshop took place as an American Society of Hematology (ASH) Friday Scientific Workshop titled "Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma." This workshop focused on 4 main topics: the molecular and immunologic evolution of plasma cell disorders, development of new laboratory- and imaging-based MRD assessment approaches, chimeric antigen receptor T cell therapy research, and statistical and regulatory issues associated with novel clinical endpoints. In this report, we provide a summary of the workshop and discuss future directions.Entities:
Keywords: CAR T cell; Endpoint; Immune profiling; Minimal residual disease; Multiple myeloma
Mesh：
Year: 2020 PMID： 32589921 PMCID： PMC7529908 DOI： 10.1016/j.bbmt.2020.06.011
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN： 1083-8791 Impact factor: 5.742